Related Experiment Video
Updated: Jan 31, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer
Yingqiu Xie1, Haiyan Fan2, Wenfu Lu3
1Department of Biology, Nazarbayev University School of Science and Technology, Astana, 010000, Kazakhstan. xieautumnus@yahoo.com.
Abstract:
Nuclear receptor tyrosine kinases (nRTKs) are aberrantly upregulated in many types of cancers, but the regulation of nRTK remains unclear. We previously showed androgen deprivation therapy (ADT) induces nMET in castration-resistant prostate cancer (CRPC) specimens. Through gene expression microarray profiles reanalysis, we identified that nMET signaling requires ARF for CRPC growth in Pten/Trp53 conditional knockout mouse model. Accordingly, aberrant MET/nMET elevation correlates with ARF in human prostate cancer (PCa) specimens. Mechanistically, ARF elevates nMET through binding to MET cytoplasmic domain to stabilize MET. Furthermore, carbon nanodots resensitize cancer cells to MET inhibitors through DNA damage response. The inhibition of phosphorylation by carbon nanodots was identified through binding to phosphate group of phospho-tyrosine via computational calculation and experimental assay. Thus, nMET is essential to precision therapy of MET inhibitor. Our findings reveal for the first time that targeting nMET axis by carbon nanodots can be a novel avenue for overcoming drug resistance in cancers especially prostate cancer.
Insights
Androgen deprivation therapy (ADT) can increase nMET in prostate cancer. Carbon nanodots overcome resistance to MET inhibitors by inducing DNA damage, offering a new strategy for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Nuclear receptor tyrosine kinases (nRTKs) are frequently upregulated in various cancers, yet their regulatory mechanisms remain largely unknown.
- Androgen deprivation therapy (ADT) has been observed to induce nMET in castration-resistant prostate cancer (CRPC) specimens.
- The precise role and regulation of nMET in cancer progression, particularly in prostate cancer, require further elucidation.
Purpose of the Study:
- To investigate the regulatory mechanisms of nMET in castration-resistant prostate cancer (CRPC).
- To explore the potential of carbon nanodots in overcoming resistance to MET inhibitors.
- To identify novel therapeutic strategies targeting the nMET axis for improved cancer treatment.
Main Methods:
- Reanalysis of gene expression microarray profiles from a Pten/Trp53 conditional knockout mouse model.
- Correlation analysis of MET/nMET and ARF expression in human prostate cancer (PCa) specimens.
- Biochemical assays and computational calculations to determine the mechanism of carbon nanodot action on MET phosphorylation.
Main Results:
- nMET signaling was identified as essential for CRPC growth, requiring ARF.
- Aberrant MET/nMET elevation was found to correlate with ARF in human PCa specimens.
- Carbon nanodots resensitize cancer cells to MET inhibitors by inducing DNA damage response and inhibiting phosphorylation.
Conclusions:
- ARF stabilizes MET, thereby elevating nMET and promoting CRPC growth.
- Targeting the nMET axis with carbon nanodots represents a novel strategy for overcoming drug resistance in cancers, particularly prostate cancer.
- Carbon nanodots offer a promising approach to enhance the efficacy of MET inhibitors in precision therapy.
Related Concept Videos
Nuclear Binding Energy
Nuclear Fusion
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
Nuclear Stability
To hold positively charged protons together...
Feedback Inhibition
Nuclear Fission
Receptor Tyrosine Kinases

